In the intention to treat population, microbiologic cure at urogenital sites was documented in 55 of 57 (96%) who received 2 g of zoliflodacin, 54 of 56 (96%) who received 3 g of zoliflodacin, and 28 of 28 (100%) who received single 500mg intramuscular dose of ceftriaxone.
According to an editorial, studies like this are a step forward in the quest to identify new antimicrobial options for gonorrhoea treatment, and given the challenges in clinical follow-up in this patient population, the single-dose regimen is promising. It notes that though the study was small, the efficacy shown is encouraging, and zoliflodacin has the potential to be an effective antibiotic for treating gonorrhoea, though the limited activity observed in key anatomical sites of infection such as the pharynx will need to be better defined.